Which is Better? Combined or Sequential approach of Cataract Surgery and Bevacizumab for patients with both Cataract and Diabetic Macular Edema problem

Comparative Study on the effectiveness of Combined Cataract Surgery with Intravitreal Bevacizumab Versus Sequential Intravitreal Bevacizumab Followed by Cataract Surgery in Diabetic Macular Edema. - Nil

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2024/12/078209

Enrollment

Registered

2024-12-17

Start date

Unknown

Completion date

Unknown

Last updated

2025-02-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: H00-H59- Diseases of the eye and adnexa Health Condition 2: H36- Retinal disorders in diseases classified elsewhere

Interventions

Control Intervention1: Intravitreal Injection Bevacizumab: Drug : Bevacizumab(Anti VEGF)

Dose : 1.25 mg in 0.05 ml

Route of administration: Intravitreal injection

Frequency: 1 injection

Follow op period: 6 months

Method : Patients with both Cataract and Diabetic Macular Edema selected, divided into 2 groups, one group (interventional arm) will undergo cataract surgery along with Intravitreal Bevacizumab in sin

Eligibility

Inclusion criteria

Inclusion criteria: Diabetic patients with immature cataract with varying levels of diabetic Retinopathy with Diabetic macular edema with or without treated with Pan Retinal Photocoagulation in the past Visual Acuity less than (6/18)

Exclusion criteria

Exclusion criteria: Catarct due to other causes such as traumatic , developmental, complicated cataract Advanced Diabetic Eye Disease , Vitreous Haemorrhage, Tractional membranes, History of ocular trauma Prior or concomitant surgery such as vitreoretinal surgery , glaucoma surgery in the operated eye, intraoperative complications. History of Uveitis, Presence of any retinal or choroidal disease(such as Retinal Vein Occlusion, Ocular Ischemic Syndrome, and Age related Macular Degeneration) , systemic conditions other than diabetes, that could affect retinal thickness .

Design outcomes

Primary

Measure	Time frame
Changes in Macula using SD – OCT both Qualitative (central macular thickness ) and Quantitatively.Timepoint: within 1 week preoperative period,post operatively 14 days, 1 month, 3 month and 6 month.	—

Secondary

Measure	Time frame
Visual Acuity using Snellens chart.Timepoint: 1 day, 7 days, 14 days, 30 days, then monthly for 6 months after surgery.	—

Countries

India

Contacts

Public ContactDr CHITRA N

REGIONAL INSTITUTE OF OPHTHALMOLOGY and GOVERNMENT OPHTHALMIC HOSPITAL

drrskalai@gmail.com9840365372

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026